DK172953B1 - Fremgangsmåde til fremstilling af erythropoietin, DNA-sekvens indkodende erythropoietin, vektor indeholdende DNA-sekvensen - Google Patents

Fremgangsmåde til fremstilling af erythropoietin, DNA-sekvens indkodende erythropoietin, vektor indeholdende DNA-sekvensen Download PDF

Info

Publication number
DK172953B1
DK172953B1 DK198603687A DK368786A DK172953B1 DK 172953 B1 DK172953 B1 DK 172953B1 DK 198603687 A DK198603687 A DK 198603687A DK 368786 A DK368786 A DK 368786A DK 172953 B1 DK172953 B1 DK 172953B1
Authority
DK
Denmark
Prior art keywords
epo
dna
sequence
cells
erythropoietin
Prior art date
Application number
DK198603687A
Other languages
Danish (da)
English (en)
Other versions
DK368786A (da
DK368786D0 (da
Inventor
Edward Fritsch
Rodney M Hewick
Kenneth Jacobs
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27418329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK172953(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of DK368786A publication Critical patent/DK368786A/da
Publication of DK368786D0 publication Critical patent/DK368786D0/da
Application granted granted Critical
Publication of DK172953B1 publication Critical patent/DK172953B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK198603687A 1984-12-04 1986-08-01 Fremgangsmåde til fremstilling af erythropoietin, DNA-sekvens indkodende erythropoietin, vektor indeholdende DNA-sekvensen DK172953B1 (da)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US67781384A 1984-12-04 1984-12-04
US67781384 1984-12-04
US68862285A 1985-01-03 1985-01-03
US68862285 1985-01-03
US69325885A 1985-01-22 1985-01-22
US69325885 1985-01-22
US8502405 1985-12-03
PCT/US1985/002405 WO1986003520A1 (en) 1984-12-04 1985-12-03 Method for the production of erythropoietin

Publications (3)

Publication Number Publication Date
DK368786A DK368786A (da) 1986-08-01
DK368786D0 DK368786D0 (da) 1986-08-01
DK172953B1 true DK172953B1 (da) 1999-10-18

Family

ID=27418329

Family Applications (4)

Application Number Title Priority Date Filing Date
DK198603687A DK172953B1 (da) 1984-12-04 1986-08-01 Fremgangsmåde til fremstilling af erythropoietin, DNA-sekvens indkodende erythropoietin, vektor indeholdende DNA-sekvensen
DK95197A DK173254B1 (da) 1984-12-04 1997-08-20 Fremgangsmaede til fremstilling af rekombinant humant erythropoietin
DK199901147A DK173293B1 (da) 1984-12-04 1999-08-20 Fremgangsmåde til fremstilling af humant erythropoietin
DK200000527A DK175826B1 (da) 1984-12-04 2000-03-29 Fremgangsmåde til fremstilling af rekombinat erythropoietin

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK95197A DK173254B1 (da) 1984-12-04 1997-08-20 Fremgangsmaede til fremstilling af rekombinant humant erythropoietin
DK199901147A DK173293B1 (da) 1984-12-04 1999-08-20 Fremgangsmåde til fremstilling af humant erythropoietin
DK200000527A DK175826B1 (da) 1984-12-04 2000-03-29 Fremgangsmåde til fremstilling af rekombinat erythropoietin

Country Status (24)

Country Link
EP (2) EP0205564B2 (ro)
JP (4) JPH0655144B2 (ro)
KR (1) KR890001011B1 (ro)
AT (2) ATE71408T1 (ro)
AU (1) AU621535B2 (ro)
CA (1) CA1341502C (ro)
CZ (3) CZ281756B6 (ro)
DE (3) DE411678T1 (ro)
DK (4) DK172953B1 (ro)
ES (1) ES8800049A1 (ro)
FI (2) FI104261B1 (ro)
GE (1) GEP19970775B (ro)
GR (1) GR852890B (ro)
HK (2) HK105593A (ro)
HU (1) HU216079B (ro)
IL (1) IL77081A (ro)
LV (2) LV10505B (ro)
MD (1) MD1639C2 (ro)
NO (1) NO304469B1 (ro)
PL (2) PL154180B1 (ro)
PT (1) PT81590B (ro)
SK (2) SK279765B6 (ro)
UA (1) UA44882C2 (ro)
WO (1) WO1986003520A1 (ro)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
EP0236059B1 (en) * 1986-02-27 1994-04-27 Snow Brand Milk Products Co. Ltd. Preparation of erythropoietin-producing cells and production process of erythropoietin using same
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
DK175363B1 (da) * 1986-09-12 2004-09-13 Genentech Inc Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
EP0752474A1 (en) 1995-07-07 1997-01-08 Boehringer Mannheim Gmbh Nucleic acid coding for CMP-N-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
JPH10510434A (ja) * 1995-07-07 1998-10-13 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｍｐ−ｎ−アセチルノイラミン酸ヒドロキシラーゼをコードする核酸及び修飾糖タンパク質の産生のためのその使用
DE19535571A1 (de) 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
IL131959A0 (en) 1997-03-18 2001-03-19 Roche Diagnostics Gmbh Pharmaceutical combined preparations containing erythropoietin and iron preparations
EP0885613A1 (de) 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
DK0986644T3 (da) * 1997-07-23 2007-01-29 Roche Diagnostics Gmbh Fremstilling af erythropoietin ved endogen genaktivering med virale promotorer
US6395484B1 (en) * 1997-07-23 2002-05-28 Roche Diagnostics Gmbh Identification of human cell lines for the production of human proteins by endogenous gene activation
PT986644E (pt) 1997-07-23 2007-01-31 Roche Diagnostics Gmbh Preparação de eritropoietina por activação genética endógena com promotores virais
PT1000154E (pt) 1997-07-23 2007-03-30 Roche Diagnostics Gmbh Identificação de linhas celulares humanas para a produção de proteínas humanas por activação endógena de genes
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
ES2208798T3 (es) * 1997-09-01 2004-06-16 Aventis Pharma Deutschland Gmbh Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso.
AR019025A1 (es) 1998-04-09 2001-12-26 Roche Diagnostics Gmbh Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
BR9905867A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
BR9917606A (pt) 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
BR9905868A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
WO2003048348A2 (en) 2001-12-07 2003-06-12 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
AU3323002A (en) 2000-12-20 2002-07-01 Hoffmann La Roche Erythropoietin conjugates
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
KR100505152B1 (ko) * 2001-09-10 2005-08-03 (주)가이아진 아스코르브산을 이용한 에리트로포이에틴의 생산방법
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
BR0314107A (pt) 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Método de produção de derivados de hidroxialquil amido
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
AU2003273413A1 (en) 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
EA008670B1 (ru) 2003-05-09 2007-06-29 Круселл Холланд Б.В. Культуры e1-иммортализованных клеток и способы их культивирования с целью повышения выхода их продукции
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP1670492A4 (en) 2003-09-29 2009-07-08 Warren Pharmaceuticals Inc FABRIC PROTECTION CYTOKINES FOR THE TREATMENT AND PREVENTION OF SEPTICEMIA AND THE FORMATION OF ADHESIONS
RU2542391C2 (ru) 2003-12-30 2015-02-20 Аугустинус БАДЕР Способ регенерации ткани
DE102004063927A1 (de) 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
WO2005092391A2 (en) 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
AR048035A1 (es) 2004-03-11 2006-03-22 Fresenius Kabi De Gmbh Conjugados de almidon de hidroxialquilo y una proteina, preparados por aminacion reductora
GB0507123D0 (en) * 2005-04-08 2005-05-11 Isis Innovation Method
EP1762250A1 (en) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
AR053416A1 (es) * 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
TW200804415A (en) 2006-01-18 2008-01-16 Chugai Pharmaceutical Co Ltd Method of removing sialic acid and process for producing asialoerythropoietin
DE102006004008A1 (de) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
EP1991569A4 (en) * 2006-03-07 2009-12-23 Regenetech Inc MAMMALIAN BIOLOGICAL MOLECULES WITH NATURAL GLYCOSYLATION PRODUCED BY ELECTROMAGNETIC STIMULATION OF LIVING MAMMALIAN CELLS
JP5553506B2 (ja) 2006-03-22 2014-07-16 中外製薬株式会社 エリスロポエチン溶液製剤
WO2008019214A1 (en) 2006-08-04 2008-02-14 Prolong Pharmaceuticals, Inc. Modified erythropoietin
WO2009010107A1 (en) 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
EP2095829A1 (en) 2008-02-27 2009-09-02 LEK Pharmaceuticals D.D. Selenium containing modifying agents and conjugates
DE102008002209A1 (de) 2008-06-04 2009-12-10 Evonik Degussa Gmbh Verfahren zur Aufreinigung von Erythropoietin
DE102008002210A1 (de) 2008-06-04 2009-12-10 Evonik Degussa Gmbh Verfahren zur fermentativen Herstellung von Erythropoietin
EP2334699B1 (en) 2008-09-23 2013-09-11 F. Hoffmann-La Roche AG Purification of erythropoietin
DE102008054716A1 (de) 2008-12-16 2010-06-17 Evonik Degussa Gmbh Inprozesskontrolle in einem Verfahren zur Herstellung von EPO
US20100272816A1 (en) 2009-04-27 2010-10-28 Wolfgang Rudinger Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
CA2775012A1 (en) 2009-09-23 2011-03-31 Biogenerix Ag Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same
WO2017068051A1 (en) 2015-10-21 2017-04-27 Lek Pharmaceuticals D.D. Peg-based dendron and process for producing the same
CN106906359B (zh) 2015-12-22 2018-12-11 理查德.亨威克 从硅酸盐矿物收取锂
JP2020511499A (ja) 2017-03-20 2020-04-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 赤血球生成刺激タンパク質のインビトロでの糖鎖改変のための方法
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US439780A (en) * 1890-11-04 Method of and apparatus for casting ingots
US3865801A (en) * 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
JPS5455790A (en) * 1977-10-05 1979-05-04 Tomoyuki Tajima Production of erythropoetin
JPS5653696A (en) * 1979-10-09 1981-05-13 Ajinomoto Co Inc Isolation of erythropoietin by adsorption
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4419446A (en) * 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
JPS6043395A (ja) * 1983-08-19 1985-03-07 Sumitomo Chem Co Ltd エリスロポエチンの製造法
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IT1185503B (it) * 1984-01-11 1987-11-12 Univ New York Cloni di odna di eritropietina umana
JPS60215632A (ja) * 1984-04-12 1985-10-29 Japan Found Cancer エリスロポエチンの製造法
US4732889A (en) * 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
JPH062070B2 (ja) * 1988-07-06 1994-01-12 農林水産省食品総合研究所長 ▲ｏ下−▼アシルアミノ酸の製造方法

Also Published As

Publication number Publication date
MD1639B2 (ro) 2001-03-31
PL256589A1 (en) 1986-10-21
GEP19970775B (en) 1997-01-27
NO304469B1 (no) 1998-12-21
DK173293B1 (da) 2000-06-13
DK175826B1 (da) 2005-03-14
DK95197A (da) 1997-08-20
HK105693A (en) 1993-10-15
JPH02104284A (ja) 1990-04-17
DK200000527A (da) 2000-03-29
HU216079B (hu) 1999-04-28
DE3582732D1 (de) 1991-06-06
GR852890B (ro) 1986-04-03
WO1986003520A1 (en) 1986-06-19
CZ127496A3 (cs) 2000-02-16
EP0411678B1 (en) 1992-01-08
FI19992064A (fi) 1999-09-27
FI863044A (fi) 1986-07-24
JPH02442A (ja) 1990-01-05
KR870700099A (ko) 1987-02-28
IL77081A0 (en) 1986-04-29
EP0205564A1 (en) 1986-12-30
UA44882C2 (uk) 2002-03-15
LV10507B (lv) 1996-06-20
CA1341502C (en) 2006-03-21
ES549539A0 (es) 1987-10-16
SK168799A3 (en) 2001-08-06
CZ287620B6 (cs) 2001-01-17
LV10505B (en) 1996-04-20
DE3585161D1 (de) 1992-02-20
EP0205564B1 (en) 1991-05-02
AU5313486A (en) 1986-07-01
SK880485A3 (en) 1999-03-10
SK279765B6 (sk) 1999-03-12
IL77081A (en) 1999-10-28
NO863050L (no) 1986-07-28
JPH07184681A (ja) 1995-07-25
ATE63137T1 (de) 1991-05-15
AU621535B2 (en) 1992-03-19
ES8800049A1 (es) 1987-10-16
DE411678T1 (de) 1991-10-17
KR890001011B1 (en) 1989-04-18
PT81590A (en) 1986-01-01
DK173254B1 (da) 2000-05-22
CZ880485A3 (en) 1996-08-14
PL154180B1 (en) 1991-07-31
NO863050D0 (no) 1986-07-28
JPH0655144B2 (ja) 1994-07-27
PT81590B (pt) 1987-10-20
CZ286557B6 (cs) 2000-05-17
FI104261B (fi) 1999-12-15
FI104261B1 (fi) 1999-12-15
CZ281756B6 (cs) 1997-01-15
EP0205564B2 (en) 2000-06-21
HK105593A (en) 1993-10-15
DK199901147A (da) 1999-08-20
DK368786A (da) 1986-08-01
EP0411678A1 (en) 1991-02-06
SK281799B6 (sk) 2001-08-06
MD1639C2 (ro) 2001-10-31
EP0205564A4 (en) 1987-12-14
PL157926B1 (pl) 1992-07-31
EP0411678B2 (en) 2000-01-12
FI863044A0 (fi) 1986-07-24
FI105347B (fi) 2000-07-31
LV10507A (lv) 1995-02-20
JPH01257480A (ja) 1989-10-13
MD940371A (ro) 1996-06-28
ATE71408T1 (de) 1992-01-15
DK368786D0 (da) 1986-08-01
HUT40706A (en) 1987-01-28
LV10505A (lv) 1995-02-20

Similar Documents

Publication Publication Date Title
DK172953B1 (da) Fremgangsmåde til fremstilling af erythropoietin, DNA-sekvens indkodende erythropoietin, vektor indeholdende DNA-sekvensen
JP2957974B2 (ja) エリスロポエチン活性を有するタンパク質の製造方法
EP0689592B1 (en) Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
US6682910B2 (en) Human erythropoietin gene: high level expression in stably transfected mammalian cells
RU2129613C1 (ru) Способ получения эритропоэтина человека
JPH0144317B2 (ro)
AU5711199A (en) Method for the production of erythropoietin

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PPF Opposition filed
PDQ Request for opposition withdrawn
PUP Patent expired